ArticleMolecular biology reports2025
Vitamin D3 augments cytotoxic effect of Itraconazole on chronic myelogenous leukemia cell line: a synergic effect on AMPK/AKT signaling pathway.
Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGrowing documents suggest combination therapy as an effective tool to treat the resistant cancer cells. Accordingly, in this study, it has been hypothesized that a combination of Vitamin D3(VD) and Itraconazole can inhibit Chronic Myeloid Leukemia(CML) K562 cells in vitro. METHODS AND
resultsK562 cells were incubated with different concentrations of either VD or Itraconazole either alone or in combination. The results showed that Itraconazole, VD, and combination treatment reduced the cell viability in a time and dose-dependent manner (P < 0.0001). In addition, the apoptosis rate was significantly induced in cells treated with combination drug (P < 0.0001). The Bax/Bcl-2 ratio was increased in treated cells, whereas the subcellular distribution of β-catenin protein was reduced. Morever, the phosphorylation of AKT and p65 were increased, whereas AMPK phosphorylation was decreased in treated cells (P < 0.0001).
conclusionOur results show that VD and Itraconazole synergically inhibit K562 cells viability via activation of AMPK and suppression of AKT function, suggesting that this combinational therapy potentially benefits CML patients.
Indexed as
Identifiers
40522383What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.